GlaxoSmithKline, Britain’s biggest pharmaceutical group,
has been selling anti-depressant drugs in the US for unapproved uses on children,
concealing critical evidence from US regulator the Food and Drug Administration (FDA) relating to a diabetes product,
and offering lavish entertainment to doctors willing to promote its medicines.
The problems came to light
because of whistleblowers inside the company
and adds to a string of other settlements with pharmaceutical firms
that lead critics to claim problems are endemic in the sector.